^
almost2years
Methotrexate and Triptolide regulate Notch signaling pathway by targeting the Nedd4-Numb axis. (PubMed, Int Immunopharmacol)
Interestingly, we found that a monomeric drug, Triptolide, is capable of alleviating the inhibitory effect of MTX on Notch signaling pathway. This study promotes our understanding of MTX-mediated regulation of Notch signaling and could provide ideas to alleviate MTX-induced myelosuppression.
Journal
|
NOTCH1 (Notch 1)
|
methotrexate • TriptoSar (omtriptolide)
almost2years
Screening of major hepatotoxic components of Tripterygium wilfordii based on hepatotoxic injury patterns. (PubMed, BMC Complement Med Ther)
Parthenolide, triptolide, triptonide, celastrol, demethylzeylasteral, triptotriterpenic acid A and triptobenzene H might be the main hepatotoxic components of TwFH. Among them, only triptotriterpenic acid A presents direct hepatotoxicity. Triptobenzene H exerts indirect liver damage by activating macrophages. Parthenolide, triptolide, triptonide, celastrol, and demethylzeylasteral can directly and indirectly cause liver injury.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
|
TriptoSar (omtriptolide)
almost2years
Network pharmacology, molecular docking and bioinformatics reveal the mechanism of Tripterygii Wilfordii against Osteosarcoma. (PubMed, Medicine (Baltimore))
Upregulation of the cellular tumor antigen p53 (TP53) gene and downregulation of peroxisome proliferator-activated receptor gamma (PPARG) and signal transducer and activator of transcription 1-alpha/beta (STAT1) genes can prolong the survival time of patients with OS. Triptolide, kaempferol, and 5,8-Dihydroxy-7-(4-hydroxy-5 methyl-coumarin-3)-coumarin have a relatively high potential to become a treatment for patients with OS and improve 5-year survival of OS patients.
Journal
|
PPARG (Peroxisome Proliferator Activated Receptor Gamma) • STAT1 (Signal Transducer And Activator Of Transcription 1)
|
TriptoSar (omtriptolide)
almost2years
Triptolide promotes ferroptosis by suppressing Nrf2 to overcome leukemia cell resistance to doxorubicin. (PubMed, Mol Med Rep)
Notably, the present study showed that triptolide re‑sensitized DOX‑resistant leukemia cells to DOX. In conclusion, the present study indicated that Nrf2 served a critical role in leukemia cell resistance to DOX and triptolide‑induced ferroptosis and suggested a potential strategy of combination therapy using triptolide and DOX in leukemia treatment.
Journal
|
NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • GPX4 (Glutathione Peroxidase 4)
|
GPX4 expression
|
doxorubicin hydrochloride • TriptoSar (omtriptolide)
almost2years
Triptolide Inhibits the Biological Processes of HUVECs and HepG2 Cells via the Serine Palmitoyltransferase Long Chain Base Subunit 2/Sphingosine-1-Phosphate Signaling Pathway. (PubMed, Dis Markers)
In conclusion, SPTLC2 may be associated with the antivascular and antitumor effects of TP, and SPTLC2 is expected to become a new marker for tumor therapy. HUVECs can promote the proliferation, migration, and invasion of HepG2 cells, which may be related to the S1P/sphingosine-1-phosphate receptor (S1PR) signaling pathway.
Journal
|
S1PR1 (Sphingosine-1-Phosphate Receptor 1)
|
TriptoSar (omtriptolide)
2years
Triptolide-mediated downregulation of FLIP in hepatoma cells occurs at the post-transcriptional level independently of proteasome-mediated pathways. (PubMed, Med Oncol)
Subsequently, we showed that TPL reduced FLIP level in a transcription- and degradation-independent mechanism. Our findings suggest that TPL induces loss of FLIP at the post-transcriptional level independently of proteasome-mediated pathway, an additional mechanism of TPL sensitizing cancer cells to TNF-α-induced apoptosis.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • BIRC3 (Baculoviral IAP repeat containing 3) • CASP8 (Caspase 8)
|
TriptoSar (omtriptolide)
2years
A mitochondria-targeted nano-platform for pancreatic cancer therapy. (PubMed, Front Chem)
Herein, a novel platform for anti-tumor drug delivery was developed by incorporating an amphiphilic stachydrine-octadecane conjugate (SS) as the mitochondria-targeting molecule onto the triptolide-liposome surfaces (SS-TP LPs)...In the Pan02 tumor-bearing mice, the SS-TP LPs showed significant efficacy in inhibiting tumor growth and reducing tumor size but synchronously exhibited specific mitochondria-targeting and much lower subacute toxicity compared with the free TP and TP LPs. Our study suggests that SS-TP LPs can be a promising anticancer drug delivery system for mitochondria-targeted therapy in pancreatic cancer.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
TriptoSar (omtriptolide)
2years
In vitro, in vivo and molecular effects of triptolide and minnelide in renal cell carcinoma (KCRS 2022)
The profound antitumor effects in the aggressive 786-0 RCC xenograft model are highly encouraging and warrant further preclinical studies and potential clinical trials of M this devastating disease. Correlative tumor studies to understand the mechanisms of M in vivo antitumor effects are underway and will be presented at the meeting.
Preclinical
|
CASP3 (Caspase 3) • EIF2A (Eukaryotic Translation Initiation Factor 2A) • EIF2S1 (Eukaryotic Translation Initiation Factor 2 Subunit Alpha)
|
minnelide • TriptoSar (omtriptolide)
2years
Novel EGFR/PI3K dual-targeting nanoparticles induce immunogenic cell death in bladder cancer (SITC 2022)
Methods Herein, we identified two natural products triptolide (TPL) and hesperidin (HSP), dual targeting EGFR and PI3Kin BCa by network pharmacology and molecular modeling...Immunogenic cell death markers HMGB1 and CRT levels were evaluated both in vitro and in vivo after treatment so as to inhibit BCa proliferation and tumor growth. Conclusions Dual targeting nanoparticle may emerge as a novel paradigm in BCa treatment, providing a new approach for inducing immunogenic cell death in BCa care.
EGFR (Epidermal growth factor receptor) • HMGB1 (High Mobility Group Box 1)
|
EGFR overexpression
|
TriptoSar (omtriptolide)
2years
The Antigastric Cancer Effect of Triptolide is Associated With H19/NF-κB/FLIP Axis. (PubMed, Front Pharmacol)
TP pretreatment increased apoptosis in TNF-α-stimulated gastric cancer cells, which are dependent on the disruption of the H19/miR-204-5p/NF-κB/FLIP axis. Cotreatment of TP and TNF-α is a better option for enhancing the anticancer effect and lowering the side effect of TP.
Journal
|
H19 (H19 Imprinted Maternally Expressed Transcript) • MIR204 (MicroRNA 204)
|
TriptoSar (omtriptolide)
2years
Regulation of dietary polyphenols on cancer cell pyroptosis and the tumor immune microenvironment. (PubMed, Front Nutr)
These dietary polyphenols include curcumin (CUR), resveratrol (RES), epigallocatechin gallate (EGCG), apigenin, triptolide (TPL), kaempferol, genistein and moscatilin...Dietary polyphenols are also used with radiotherapy and chemotherapy to improve antitumor immunity and shape a beneficial TIME. In conclusion, dietary polyphenols induce cancer cell pyroptosis and regulate the TIME, providing new ideas for safer cancer cures.
Review • Journal
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
TriptoSar (omtriptolide)
over2years
NCI-2021-12558: Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1b, N=30, Recruiting, City of Hope Medical Center | Initiation date: Jul 2022 --> Mar 2022
Trial initiation date
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
|
Tagrisso (osimertinib) • minnelide • TriptoSar (omtriptolide)
over2years
Triptolide attenuates LPS-induced activation of RAW 264.7 macrophages by inducing M1-to-M2 repolarization via the mTOR/STAT3 signaling. (PubMed, Immunopharmacol Immunotoxicol)
Overall, our results indicated that TP attenuated LPS-induced activation of RAW 264.7 macrophages by inducing M1-to-M2 repolarization via repression of the mTOR/STAT3 signaling. Therefore, TP might be an effective agent for IBD treatment.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
|
TriptoSar (omtriptolide)
over2years
Targeting Nrf2 in non-small cell lung cancer: triptolide as a potential adjuvant chemotherapy (EACR 2022)
Triptolide also sensitised cells to gemcitabine and induced apoptosis in a 3D model of NSCLC. Brusatol has off-target effects; however, triptolide may have potential use as a targeted adjuvant therapy in NSCLC.
Clinical
|
NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • CASP3 (Caspase 3) • NQO1 (NAD(P)H dehydrogenase, quinone 1) • CASP7 (Caspase 7)
|
gemcitabine • TriptoSar (omtriptolide)
over2years
Triptolide promotes degradation of the unfolded gain-of-function Tp53 mutant protein by initiating heat shock protein 70 transcription in non-small cell lung cancer. (PubMed, Transl Lung Cancer Res)
Moreover, by upregulating HSP70 transcription, triptolide contributed to the protein degradation of the GOF mutp53. Our study reports, for the first time, the mechanism underlying triptolide-regulated protein degradation of TP53 or TP53, which offers new insight into developing a better therapeutic strategy for patients with NSCLC who express the unfolded mutp53 GOF protein.
Journal
|
TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
|
TP53 mutation • TP53 wild-type • TP53 expression
|
TriptoSar (omtriptolide)
over2years
NCI-2021-12558: Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1b, N=30, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
|
Tagrisso (osimertinib) • minnelide • TriptoSar (omtriptolide)
over2years
Triptolide inhibits T-cell acute lymphoblastic leukaemia by affecting aberrant epigenetic events in the Wnt signalling pathway. (PubMed, J Chemother)
Further analysis indicated that TPL induced the demethylation of these genes, which may be related to the inhibited expression of methyltransferases DNMT1 and DNMT3a. In conclusion, our results suggest that TPL inhibits T-ALL by inhibiting aberrant epigenetic events in dysregulated Wnt signalling.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • DNMT3A (DNA methyltransferase 1) • CDH1 (Cadherin 1) • DNMT1 (DNA methyltransferase 1) • SOX17 (SRY-Box Transcription Factor 17) • WIF1 (WNT Inhibitory Factor 1) • TCF7 (Transcription Factor 7)
|
MYC expression
|
TriptoSar (omtriptolide)
over2years
Venetoclax in Acute Myeloid Leukemia. (PubMed, Recent Pat Anticancer Drug Discov)
The management of unfit and older patients with acute myeloid leukemia should be personalized and be the result of evaluating patient- and disease-specific factors that are essential to their care. Combinations that include venetoclax are an increasingly well-documented option for many of them.
Journal • IO biomarker
|
FLT3 (Fms-related tyrosine kinase 3)
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • lapatinib • Epidaza (chidamide) • mivebresib (ABBV 075) • TriptoSar (omtriptolide)
over2years
Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer. (PubMed, Theranostics)
Triptolide (TP), a potent cytotoxin was then set as the model payload for dextran conjugation...Furthermore, the conjugate attained a more favorable therapeutic outcome in the tumor immune microenvironment than the free drug, preserving the fraction of T cells and their effector cytokines. In summary, macropinocytic dextran was able to provide drug delivery selectivity towards KRAS mutant cancer cells and reduce tumor immunity depletion caused by the cytotoxic drug in pancreatic cancer.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS wild-type • RAS wild-type
|
TriptoSar (omtriptolide)
over2years
Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways. (PubMed, Exp Hematol Oncol)
Our results revealed that Triptolide monotherapy exerted its antileukemia effect via both p53-dependent and independent ways, with the latter through perturbation of the MYC-ATF4 axis-mediated ER stress. Collectively, these data suggested that the Triptolide-Nutlin-3a combination might be a novel potential therapeutic intervention for patients with AML and it warrants further clinical evaluations.
Journal
|
MCL1 (Myeloid cell leukemia 1) • MDM2 (E3 ubiquitin protein ligase) • XIAP (X-Linked Inhibitor Of Apoptosis) • ATF4 (Activating Transcription Factor 4) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
TP53 wild-type • TP53 expression
|
Nutlin-3 • TriptoSar (omtriptolide)
over2years
Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer. (PubMed, J Nanobiotechnology)
Overall, our findings may provide a translational strategy to overcome cisplatin-resistant OC and offer a potential solution for the treatment of other cisplatin-resistant tumors.
Journal
|
CD47 (CD47 Molecule) • MIR497 (MicroRNA 497)
|
cisplatin • TriptoSar (omtriptolide)
over2years
In vitro, in vivo and molecular effects of triptolide and minnelide in renal cell carcinoma (AACR 2022)
Our results have shown for the first time the potent in vitro and in vivo antitumor effects of T in RCC and the molecular changes associated with these effects. The profound antitumor effects in the aggressive 786-0 RCC xenograft model are highly encouraging and warrant further preclinical studies and potential clinical trials of M this devastating disease. Correlative tumor studies to understand the mechanisms of M in vivo antitumor effects are underway and will be presented at the meeting.
Preclinical
|
CASP3 (Caspase 3) • EIF2A (Eukaryotic Translation Initiation Factor 2A) • EIF2S1 (Eukaryotic Translation Initiation Factor 2 Subunit Alpha)
|
minnelide • TriptoSar (omtriptolide)
over2years
Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer. (PubMed, J Nanobiotechnology)
TPL suppressed CAFs activity and CAFs-induced cell proliferation, migration and chemotherapy resistance to SN38 of GC. CAFs-targeted TPL and SN38 co-delivery nanoparticles exhibited potent efficacy of antitumor and reshaping TME, which was a promising strategy to treat advanced GC.
Journal
|
FAP (Fibroblast activation protein, alpha)
|
TriptoSar (omtriptolide)
over2years
NCI-2021-12558: Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer (clinicaltrials.gov)
P1b, N=30, Not yet recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Initiation date: Dec 2021 --> Jul 2022 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
|
Tagrisso (osimertinib) • minnelide • TriptoSar (omtriptolide)
almost3years
Triptolide increases the radiosensitivity of lung cancer cells by inhibiting DNA repair and inducing apoptosis (PubMed, Zhonghua Zhong Liu Za Zhi)
The expression level of Bcl-2 protein was (0.21±0.02), lower than (0.52±0.05) in 4 Gy group (P<0.05). Triptolide increases the radiosensitivity of radiation-induced lung cancer cells by inhibiting DNA repair and inducing apoptosis.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CHEK2 (Checkpoint kinase 2) • CASP3 (Caspase 3)
|
BCL2 expression • TP53 expression • BAX expression • ATM expression
|
TriptoSar (omtriptolide)
almost3years
New P1 trial • Combination therapy
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
|
Tagrisso (osimertinib) • minnelide • TriptoSar (omtriptolide)
almost3years
mA methyltransferase METTL3 promotes oral squamous cell carcinoma progression through enhancement of IGF2BP2-mediated SLC7A11 mRNA stability. (PubMed, Am J Cancer Res)
In conclusion, the new finding of the manuscript is that METTL3 enhances the mRNA stability of SLC7A11 via mA-mediated binding of IGF2BP2, which thus promotes OSCC progression, and triptolide inhibits OSCC by suppressing METTL3-SLC7A11 axis. Triptolide has a potential to be as an effective anti-OSCC drug targeted to METTL3.
Journal
|
SLC7A11 (Solute Carrier Family 7 Member 11) • IGF2BP2 (Insulin Like Growth Factor 2 MRNA Binding Protein 2) • METTL3 (Methyltransferase Like 3)
|
SLC7A11 expression
|
TriptoSar (omtriptolide)
almost3years
Effect of triptolide and chemotherapy on carcinoembryonic and carbohydrate antigens levels and first-line treatment of recurrent nasopharyngeal carcinoma. (PubMed, Cell Mol Biol (Noisy-le-grand))
The levels of CEA and CA19-9 in the two groups after treatment were lower than those before treatment, and the levels of CEA and CA19-9 in the combined group were lower than those in the control group (P & Lt; 0.05). The first-line treatment of recurrent nasopharyngeal Carcinoma with triprimmab combined with chemotherapy has a good clinical effect and has a broad clinical research prospect.
Clinical • Journal
|
CD8 (cluster of differentiation 8) • CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule) • CA 19-9 (Cancer antigen 19-9)
|
TriptoSar (omtriptolide)
3years
Triptolide is a Promising Therapeutic Approach in Treating Thyroid Cancer Based on in silico and in vitro Experiment. (PubMed, Drug Des Devel Ther)
We considered that triptolide could treat thyroid cancer by inhibiting cell proliferation, inducing apoptosis and inhibiting inflammatory pathways such as the NF-κB and MAPK signaling pathways. CDKN1A, c-JUN, RELA, and TP53 were involved in the antithyroid cancer mechanism of triptolide.
Preclinical • Journal
|
TP53 (Tumor protein P53) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • RELA (RELA Proto-Oncogene)
|
TP53 expression
|
TriptoSar (omtriptolide)
3years
Membrane protein-chimeric liposome-mediated delivery of triptolide for targeted hepatocellular carcinoma therapy. (PubMed, Drug Deliv)
More importantly, TPL@MP-LP treatment suppressed tumor growth but showed minimal damage to liver and renal functions. TPL exerted anticancer effects on HCC via inducing cell proliferation arrest, apoptosis, and necroptosis, and the MP-LP might be a promising delivery strategy to improve the antitumor efficacy while mitigating toxicity of TPL for HCC therapy.
Journal
|
RIPK1 (Receptor Interacting Serine/Threonine Kinase 1)
|
TriptoSar (omtriptolide)
3years
Triptolide reverses epithelial-mesenchymal transition in glioma cells via inducing autophagy. (PubMed, Ann Transl Med)
TP can inhibit glioma cell proliferation, migration, and invasion, and reverse EMT progression. The possible mechanism of EMT reversal in glioma cells is that TP induces autophagy.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • SNAI2 (Snail Family Transcriptional Repressor 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • BECN1 (Beclin 1)
|
CDH1 expression • VIM expression • ZEB1 expression
|
TriptoSar (omtriptolide)
over3years
Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy. (PubMed, Acta Pharm Sin B)
Furthermore, TP/Ce6-LP+L induced apoptosis through a caspase-3/PARP signaling pathway. Overall, TP/Ce6-LP+L is a novel potential treatment option in halting HCC progression with attenuated toxicity.
Journal
|
CASP3 (Caspase 3)
|
sorafenib • doxorubicin hydrochloride • TriptoSar (omtriptolide)
over3years
TPL Inhibits the Invasion and Migration of Drug-Resistant Ovarian Cancer by Targeting the PI3K/AKT/NF-κB-Signaling Pathway to Inhibit the Polarization of M2 TAMs. (PubMed, Front Oncol)
Many studies have confirmed that triptolide (TPL), one of the principal components of Tripterygium wilfordii, possesses broad-spectrum anti-tumor activity...Animal experiments showed that TPL, particularly TPL + cisplatin (DDP), significantly reduced the tumor burden, prolonged the life span of mice by inhibiting M2 macrophage polarization, and downregulated the levels of CD31 and CD206 (CD31 is the vascular marker and CD206 is the macrophage marker), the mechanism of which may be related to the inhibition of the PI3K/Akt/NF-κB signaling pathway...Our results highlight the importance of M2 TAMs in Epithelial Ovarian Cancer (EOC) migration ability, invasiveness, and resistance to DDP. We also preliminarily explored the mechanism governing the reversal of the polarization of M2 macrophages by TPL.
Journal
|
CD31 (Platelet and endothelial cell adhesion molecule 1) • MRC1 (Mannose Receptor C-Type 1)
|
cisplatin • TriptoSar (omtriptolide)
over3years
Identification of potential targets of triptolide in regulating the tumor microenvironment of stomach adenocarcinoma patients using bioinformatics. (PubMed, Bioengineered)
Molecular docking demonstrated a high affinity between triptolide and CXCR4. In conclusion, CXCR4 may be a therapeutic target of triptolide in the treatment of STAD patients by modulating the TME.
Clinical • Journal
|
CXCR4 (Chemokine (C-X-C motif) receptor 4)
|
TriptoSar (omtriptolide)
over3years
Novel CD44-targeting and pH/redox-dual-stimuli-responsive core-shell nanoparticles loading triptolide combats breast cancer growth and lung metastasis. (PubMed, J Nanobiotechnology)
Collectively, our results demonstrate that TPL/NPs, which combine tumor active targeting and pH/redox-responsive drug release with proapoptotic and antimobility effects, represent a promising candidate in halting breast cancer progression and metastasis while minimizing systemic toxicity.
Journal
|
CD44 (CD44 Molecule)
|
TriptoSar (omtriptolide)
over3years
Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ. (PubMed, J Exp Clin Cancer Res)
This study not only provides a new paradigm of TPL in cancer therapy, but also highlights a crucial role of mitochondrial HK-II in linking glucose metabolism with pyroptosis.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • LDHA (Lactate dehydrogenase A) • CASP3 (Caspase 3) • SLC7A11 (Solute Carrier Family 7 Member 11) • IL1B (Interleukin 1, beta) • GSDME (Gasdermin E)
|
MYC expression
|
erastin • TriptoSar (omtriptolide)
over3years
Triptolide inhibits matrix metalloproteinase-9 expression and invasion of breast cancer cells through the inhibition of NF-κB and AP-1 signaling pathways. (PubMed, Oncol Lett)
In addition, a Transwell assay revealed that triptolide reduced the ability of MCF-7 cells to invade Matrigel. These data demonstrate that the anti-invasive effect of triptolide is associated with the inhibition of ERK signaling and NF-κB and AP-1 activation, and suggest that triptolide may be a promising drug for breast cancer.
Journal
|
MMP9 (Matrix metallopeptidase 9)
|
TriptoSar (omtriptolide)
over3years
Minnelide, a prodrug, inhibits cervical cancer growth by blocking HPV-induced changes in p53 and pRb. (PubMed, Am J Cancer Res)
In the present study, we determined the efficacy of Minnelide, a prodrug which is converted to its active form (Triptolide) in vivo against cervical cancer cells. Furthermore, Minnelide treatment was more effective when combined with platinum-based chemotherapy. These studies show that Minnelide can be used to inhibit the growth of cervical cancer.
Journal
|
CASP3 (Caspase 3) • CASP7 (Caspase 7)
|
minnelide • TriptoSar (omtriptolide)
over3years
Celastrol and Triptolide Suppress Stemness in Triple Negative Breast Cancer: Notch as a Therapeutic Target for Stem Cells. (PubMed, Biomedicines)
However, when NICD 1 was ectopically overexpressed in the cells, it partially rescued proliferation and mammosphere formation of the cells, supporting the role of notch signaling. Together, these data demonstrate that targeting stem cells and the notch signaling pathway may be an effective strategy for curtailing TNBC progression.
Journal
|
ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • HES1 (Hes Family BHLH Transcription Factor 1)
|
TriptoSar (omtriptolide)
over3years
Triptolide suppresses the growth and metastasis of non-small cell lung cancer by inhibiting β-catenin-mediated epithelial-mesenchymal transition. (PubMed, Acta Pharmacol Sin)
These results demonstrate that triptolide suppresses NSCLC metastasis by targeting EMT via reducing β-catenin expression. Our study implies that triptolide may be developed as a potential agent for the therapy of NSCLC metastasis.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
|
CDH1 expression • VIM expression • ZEB1 expression
|
TriptoSar (omtriptolide)